Australia Medical Cannabis Market, by Derivative

Growth Outlook

• The Australia Medical Cannabis Market, by Derivative market is on a steady long-term growth path. Segment value stands at roughly USD 1220 Mn in 2026 and is projected to reach USD 1471 Mn by 2027 — a gain of about 21% over the forecast period, translating to a CAGR in the double digits.
• What the regional split looks like (2026): Cannabidiol leads, holding roughly 72% of segment value — the single largest regional share. Tetrahydrocannabinol is the second-largest contributor.
• By 2027, Cannabidiol alone is expected to reach USD 1063 Mn, with Tetrahydrocannabinol at USD 408 Mn.

Market Dynamics

The demand for medical cannabis in Australia has been continuously increasing in recent years due to the growing recognition of the potential health benefits of this plant. Medical cannabis is a broad term used to describe products derived from the cannabis plant that are used for medicinal purposes. In Australia, the use of medical cannabis is regulated by the Therapeutic Goods Administration (TGA), and its use is only permitted for certain medical conditions.

One of the key drivers of demand for medical cannabis derivatives in Australia is the high prevalence of chronic diseases and conditions such as chronic pain, epilepsy, and multiple sclerosis. These conditions often do not respond well to traditional treatments and can have a significant impact on an individual's quality of life. As such, many patients and healthcare professionals are turning to medical cannabis as a potential alternative treatment option.

Additionally, there has been a growing interest in natural and holistic health approaches in Australia. Medical cannabis, being a natural plant-based product, fits into this trend and has gained popularity among those seeking alternative therapies. This has led to an increase in demand for medical cannabis derivatives, such as oils, tinctures, and capsules.

Another factor contributing to the demand for medical cannabis derivatives is the growing support from the Australian government. In 2016, the federal government legalized the cultivation of medicinal cannabis, allowing for the domestic production of medical cannabis products. This has made it easier for patients to access medical cannabis, contributing to the overall demand for its derivatives.

Moreover, the increasing number of clinical trials and research studies on the potential medical benefits of cannabis has also fueled the demand for medical cannabis derivatives. As more evidence is gathered on the potential uses of medical cannabis, more patients are likely to seek it out as a treatment option, further driving demand for its derivatives.

Furthermore, as medical cannabis becomes more widely accepted, there has been a rise in the number of companies investing in the medical cannabis industry in Australia. This has led to an increase in the variety and availability of medical cannabis derivatives in the market, catering to the diverse needs and preferences of patients.

In conclusion, the demand for medical cannabis derivatives in Australia is on the rise due to the increasing prevalence of chronic diseases, growing interest in natural and holistic health approaches, government support, and ongoing research. As the industry continues to grow and evolve, it is expected that the demand for medical cannabis derivatives will also continue to increase, providing patients with more treatment options for their medical conditions.